SynBioBeta Speaker
Anthony Costa
NVIDIA
Director, Digital Biology
Anthony Costa leads NVIDIA's Digital Biology team, driving initiatives at the intersection of artificial intelligence, high-performance computing, and life sciences. His work focuses on accelerating drug discovery and biomedical research through the NVIDIA BioNeMo platform—an open-source framework for building and training deep learning models for applications spanning DNA, RNA, proteins, and molecular design.At NVIDIA, Anthony has been instrumental in forging strategic partnerships that are reshaping computational biology, helping bring together domain experts in biology and medicine with AI engineers to build next-generation foundation models for drug discovery.Prior to NVIDIA, Anthony spent nearly eight years at the Icahn School of Medicine at Mount Sinai, where he served as Founding Director of Sinai BioDesign—a needs-driven medical device incubator—and Chief Operating Officer of AISINAI, a clinical AI research group. He also held positions as Assistant Professor in the Department of Neurosurgery and as a Computational Scientist, leading translational AI initiatives in healthcare.Anthony holds a PhD from Purdue University and completed postdoctoral research at Northwestern University, where he built computational tools for non-equilibrium statistical mechanics and self-assembly. He holds a BA from Bowdoin College.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Anthony
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
